CTOR vs CYCN

Citius Oncology, Inc. vs Cyclerion Therapeutics, Inc. — Valuation Comparison 2026

CTOR

Pharmaceutical Preparations
Citius Oncology, Inc.
Quality
3.4
out of 10
Value Trap
24
SAFE
Price
$0.80
Last close
Models
9/13
Active
VS

CYCN

Pharmaceutical Preparations
Cyclerion Therapeutics, Inc.
Quality
5.5
out of 10
Value Trap
24
SAFE
Price
$3.15
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CTOR Fair ValueCTOR Upside CYCN Fair ValueCYCN Upside
Bayesian DCF Intrinsic $0.24 -70.0% $1.20 -61.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.08 -91.8% $0.45 -86.2%
Dynamic NAV Asset-Based $0.02 -98.0% $8.67 +175.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CTOR vs CYCN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CTOR vs CYCN — Which Stock Is More Undervalued?

CYCN scores higher with a 5.5/10 quality rating vs CTOR's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Citius Oncology, Inc. (CTOR) and Cyclerion Therapeutics, Inc. (CYCN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CTOR currently trades at $0.80 with a QOC of 3.4/10, while CYCN trades at $3.15 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).